25.02.2025 • NewsAir Products

Air Products to Exit Three US-Based Projects

As part of a review initiated by Air Products’ newly-elected board of directors and CEO, the company decided to exit three projects in the US. As a result, Air Products expects to record a pre-tax charge not to exceed $3.1 billion in its fiscal 2025 second quarter, primarily to write down assets and terminate contractual commitments.

The projects affected by the exit are a sustainable aviation fuel (SAF) facility with World Energy in Paramount, California, a green liquid hydrogen facility in Massena, New York, and a carbon monoxide (CO) project in Texas.

Air Products cited challenging commercial aspects surrounding the expansion project and current operations, recent regulatory developments unfavorable project economics as reasons for the cancellation of these projects.

“The decision to exit these three projects will streamline our backlog and focus company resources on projects that drive value for Air Products’ shareholders,” said Eduardo Menezes, who succeeded Seifollah (Seifi) Ghasemi as CEO of Air Products on Feb. 7.

Air Products said that it will continue to evaluate all projects in its backlog but does not currently expect any additional material cancellations going forward.

© Air Products
© Air Products

Company

Logo:

Air Products & Chem. Inc.

7201 Hamilton Blvd.
PA 18195 Allentown
US

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.